Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2025 R&D 100 Award Winners
    • 2025 Professional Award Winners
    • 2025 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

J & J Loses Price Fixing Case

By R&D Editors | December 20, 2010

HARRISBURG, Pa. (AP) – Johnson & Johnson must pay $52 million in damages and penalties after a Pennsylvania judge found the pharmaceutical company falsely reported the prices of its drugs.

Pennsylvania Attorney General Tom Corbett said Friday that a Commonwealth Court judge rendered the verdict last week after a five-week trial in Easton, Pa.

Johnson & Johnson has been ordered to repay more than $45 million to Medicaid and the PACE prescription drug program for senior citizens, along with more than $6.5 million in civil penalties.

In 2004, Corbett’s office sued Johnson & Johnson, several of its subsidiaries and 14 other drug companies, alleging they manipulated a pricing benchmark known as the “average wholesale price.” Corbett’s office has recovered $49 million so far and other cases are pending.

“Medicaid and PACE serve the most vulnerable Pennsylvanians, including low income families and seniors,” Corbett said. “Taking money from these programs by manipulating and inflating drug prices is simply unconscionable.”

Johnson & Johnson said in a statement that the trial record shows that it has acted responsibly in its drug pricing and that the state made its reimbursement decisions knowing that the average wholesale price was “a starting point for determining drug reimbursements.” The company also said it intends to pursue its arguments before the court during the next phase of the case.

A spokesman, Michael Heinley, said the company will appeal the judge’s ruling if necessary.

Date: December 17, 2010
Source: Associated Press

Related Articles Read More >

Who’s building in pharma, and who would be spared from 100% tariffs, if enacted
2025 R&D layoffs tracker: hardware and chips lead the year’s biggest cuts while biopharma pares pipelines
Skin’s built-in “stretch sensor” helps tissue grow in mouse study
Meissner launches rotary impeller mixing solutions (RMS) portfolio for biocontainer mixing
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2025 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Sign up for R&D World’s newsletter
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2025 R&D 100 Award Winners
    • 2025 Professional Award Winners
    • 2025 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE